Long acting injectable antipsychotics: Uninterrupted use during the COVID‐19 pandemic

Long-acting injectable (LAI) antipsychotics are considered the gold standard treatment option for some patients diagnosed with schizophrenia who find it difficult to maintain treatment (Haddad et al., 2014; Nystazaki et al., 2018). Some patients diagnosed with a psychotic illness experience impaired insight and judgement which increases the risk for discontinuing pharmacotherapy (Haddad et al., 2014). At the same time, data show that people...